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Abstract Erythropoietic protoporphyria (EPP) is an
inherited disorder of the porphyrin metabolism that often
remains undiagnosed in children. We report on a 4-year-old
girl who had been suffering for 1 year from recurrent
painful crises affecting her hands, feet, and nose following
sun exposure. Objective skin lesions were absent until the
age of 6. Porphyrin analysis revealed elevated free
erythrocyte protoporphyrin (FEP) levels confirming the
diagnosis of EPP. This illustrates that skin lesions might be
completely absent in children affected with EPP, a fact that
has only been reported once previously. Because EPP can
manifest with few and unspecific cutaneous symptoms or
no skin lesions at all, like in this patient, the diagnosis of
EPP might be delayed or missed. EPP should be excluded
in all photosensitive children, especially when discomfort is
disproportionate to the extent of the cutaneous lesions. The
clinic, pathophysiology, diagnosis, complications, and
therapy of EPP are discussed.
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EPP erythropoietic protoporphyria
FECH ferrochelatase
ROS reactive oxygen species
FEP free erythrocyte protoporphyrin
UV ultraviolet
UVB ultraviolet-B
ALA δ-aminolevulinic acid
Introduction
Erythropoietic protoporphyria (EPP) (OMIM 177000)
results from a partial deficiency of ferrochelatase (FECH),
the last enzyme in heme biosynthesis that is located in the
mitochondrium [10, 13]. FECH catalyzes the insertion of
iron into protoporphyrin IX to form heme (Fig. 1)[ 10].
Although overall EPP is a rare disease, it is the most
common type of porphyria manifesting in childhood with
an estimated prevalence of 1 in 130,000 [10, 13, 23].
The disease has no racial or sex predilection and no
precipitating factors have been described to date [10, 20].
The major clinical feature of EPP is cutaneous photosen-
sitivity that usually commences early in infancy or
childhood, affects the sun-exposed body sites, and worsens
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Maastricht, The Netherlandsin spring and summer [10]. The symptoms include pain,
burning, itching, erythema, and swelling, which can
develop within minutes of sun exposure [4, 10, 13, 14].
Petechiae, purpura, and vesicles may be seen, but are
uncommon [4]. Typically, children experience relief when
cooling the skin with cold water or wet towels [11].
Chronic UV (ultraviolet) exposure can lead to lichen-
ification, postinflammatory hyperpigmentation, and scar-
ring, particularly over the knuckles and on the nose [13,
23]. Of note, the cutaneous symptoms can be discrete and
barely notable in early childhood despite significant
subjective discomfort including burning and stinging
sensations in the skin.
Here, we describe a girl with EPP with an unusual
clinical course, demonstrating that parents and physicians
cannot always recognize how much the patients suffer.
Case report
An otherwise healthy, 4-year-old Dutch Caucasian girl
presented with a 1-year history of suddenly occurring
severe itching and pain in the hands, feet, and nose after
sunlight exposure. These sensations lasted up to 3 days, and
she reported on three such incidents during the last
12 months. The symptoms developed either immediately
or up to 8 h after UV exposure. Erythema or other skin
manifestations were not seen. The condition worsened in
the summer months and during vacations in sunny climates.
Itching commenced immediately after sunlight exposure
and reached a maximum at night. After a few hours, the
itching changed into pain. Application of wet towels or cold
baths led to partial relief, and the symptoms usually
vanished spontaneously after a couple of cloudy days
without intense UV exposure. Looking back, her parents
also remembered that at the age of 1 year, during a summer
vacation, she had suffered from an unexplained acute
swelling of the hands and feet. At that time no specific
diagnosis was made, besides the suspicion of an allergy.
During that vacation at the sea side, the overall family life
was disturbed because she was continuously agitated, cried
a lot without an apparent reason, and did not sleep well.
Upon physical examination in our outpatient clinic at the
age of 4, she showed no skin symptoms except for few
minimal excoriations on the dorsal aspects of the feet. The
family history revealed eczema in the mother and atopy in
the paternal grandmother, but was unremarkable regarding
increased photosensitivity. Eventually, a pediatrician sug-
gested the differential diagnoses polymorphic light erup-
tion, warmth intolerance, or hypochondria, and the girl was
treated unsuccessfully with antihistamines.
Due to continuation of her complaints, a pediatric
dermatologist was consulted who suspected EPP despite
the absence of cutaneous manifestations. Blood porphyrin
analysis revealed elevated free erythrocyte protoporphyrin
(FEP) levels of 9,821 μg/l (normal 0–300 μg/l), confirming
the diagnosis of EPP. Affirmative phototesting showed
maximal cutaneous sensitivity at a wavelength of 400 nm
(violet light). Full blood count and liver enzymes were
normal.
Therapeutically, strict UV light avoidance, protective
sunscreens, and annual follow-up visits were advised. Still,
her photosensitivity did not improve, and mild hyperpig-
mentation and sores at her nose and upper lip as well as
pronounced knuckles and progressive lichenification devel-
oped at the age of 6. To date, she has not shown liver
enzyme alterations.
Discussion
Here we present a girl with EPP who suffered from a
significant decrease of quality of life due to severe itching
and pain of the skin. Clinically, EPP is characterized by
cutaneous photosensitivity manifesting early in life. Acute
photosensitivity episodes include burning, stinging, and
pruritus in sun-exposed skin, particularly on the nose,
cheeks, and dorsal aspects of the hands, followed by
erythema, edema, and wax-like scarring. Skin symptoms
can occur within minutes of sun exposure, often starting
early in spring time, continuing through the summer, and
diminishing in fall and winter.
Interestingly though, our patient did not show any
visible skin lesions until the age of 6. Over the last 30 years
there have been ten reports on children with EPP who
developed mild to severe cutaneous photosensitivity and
specific skin manifestations [1, 2, 11, 15, 19–21, 23, 30,
31]. With mild or absent visible skin symptoms, however,
diagnosis may be delayed for several years or is not made at
all because the discomfort experienced by the young
patients is disproportionate to the objective cutaneous
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labeled as hysterical, hypochondriac, or even malingering, a
distressing situation for both the patients and their parents
[2, 22]. To the best of our knowledge the complete absence
of visible skin lesions in early childhood EPP has only been
described once to date [12].
The symptoms in EPP are associated with an overpro-
duction and accumulation of lipophilic protoporphyrin as a
result of FECH deficiency [28]. Excess deposition of
protoporphyrin in the skin leads to cutaneous photosensi-
tivity upon UV light exposure with maximum susceptibility
at a wavelength around 400 nm (Soret band) [22]. Upon
excitation, protoporphyrin exerts its phototoxic effects
through the generation of reactive oxygen species (ROS).
ROS can induce lipid peroxidation, oxidation of amino
acids, and mediator release from mast cells, contributing to
the acute photosensitivity, and protein cross-linking leading
to cell membrane damage and cell death [3, 7, 13, 17, 25].
The diagnosis of EPP is based on the clinical symptoms
and verified by a significant increase of FEP (more than
five times the normal level of 0 to 300 μg/l ) in peripheral
erythrocytes [15, 18, 28]. Since protoporphyrin is a
hydrophobic metabolite, it is not renally excreted. Hence,
urinary porphyrin values are usually normal [15, 23].
Another diagnostic modality includes fluorescence micros-
copy of erythrocytes [2, 17].
Histological changes are predominantly seen in the
upper dermis and include deposition of amorphous material
containing immunoglobulins, complement components,
glycoproteins, acid glycosaminoglycans, and lipids around
blood vessels [5, 21, 24, 26, 27, 29]. However, these
alterations are not specific. Regardless of the aforemen-
tioned finding, we emphasize that it is unnecessary to take a
skin biopsy if one of the cutaneous porphyrias is suspected
because of two reasons. Firstly, simple non-invasive
biochemical laboratory techniques can easily prove or
exclude the presumptive diagnosis of porphyria. Secondly,
any kind of external trauma, such as a biopsy or excision,
inevitably constitutes an unnecessary risk for delayed or
disturbed wound healing in porphyria patients.
The differential diagnoses of EPP include solar derma-
titis, solar urticaria, polymorphous light eruption, lipoid
proteinosis, hydroa vacciniforme, and lupus erythematosus
[2, 22]. Elevated FEP levels can also be found in lead
poisoning, anemia, renal failure, cholestasis, and liver
failure. However, these conditions are not associated with
photosensitivity [13, 18, 23].
Beside the cutaneous manifestations, the most important
concern in EPP patients is the development of cholestasis
with rapid accumulation of protoporphyrin in hepatobiliary
structures resulting in severe liver damage and hepatic
failure. Although rarely occurring, progressive liver failure
is a well-recognized complication in EPP, and about one
third of EPP patients show biochemical liver abnormalities
[6, 13]. Therefore, liver function tests should be performed
annually [13, 28]. In our patient, no liver dysfunction has
been detected so far.
Although in rare instances an autosomal recessive
inheritance pattern has been described, EPP is a predom-
inantly autosomal dominantly transmitted disorder with
incomplete penetrance resulting from mutations in the
FECH gene on chromosome 18q21.3 [31, 32]. To date,
more than 65 different FECH mutations have been
reported, reflecting the genetic heterogeneity encountered
in EPP [13, 28]. Recently, the genetic mechanisms
underlying the cutaneous symptoms in EPP have been
uncovered. It is clear now that only those individuals will
develop skin symptoms who not only inherit a heterozy-
gous FECH gene mutation on one parental allele, but also a
specific intronic FECH polymorphism on the other parental
allele [8]. Thus, clinically overt EPP results from a marked
deficiency of FECH activity below a certain threshold due
to co-inheritance of a specific FECH gene mutation with a
low-penetrance IVS3-48C allele. Recent studies indicate
that the frequency of the IVS3-48C allele shows a high
degree of variability in different ethnic groups [9]. The
identification of the molecular mechanisms underlying the
manifestation of photosensitivity in EPP certainly has to be
considered a milestone in porphyria research. Still, the
development of protoporphyrin-induced hepatic disease and
the molecular mechanisms governing the phenotype with
severe liver injury are not well understood. It seems that
other as yet unidentified factors may contribute to the
pathogenesis of severe liver failure in EPP.
The current treatment modalities for EPP are limited and
not effective in all patients [13]. In an ideal scenario, the
harmful effects of exposure to visible light should be
prevented. This can partially be achieved with sunscreens
containing titanium oxide or zinc oxide. Common
sunscreens, even those with high UV absorption capacity,
do not block visible light and, thus, have no protective
effect [2, 28].Consequent avoidance of UV light exposure
and sun protection by protective clothing remains the most
important measure in preventing acute photosensitivity and
was also advised to our patient [13, 14, 18, 28]. The
effectiveness of other modalities such as antioxidants (e.g.,
beta-carotene), cysteine, narrow-band UVB-phototherapy,
and oral antihistamines remains doubtful and is certainly
not of benefit in all patients. In the future, gene therapy
approaches might play a role in the treatment of EPP
because, e.g., normal ferrochelatase activity could be
restored in vitro by transferring a wild-type copy of the
FECH gene into cultured fibroblasts of EPP patients [16].
In conclusion, the diagnosis of EPP is often delayed or
missed. Therefore, EPP should always be considered in
photosensitive children, especially when the subjective
Eur J Pediatr (2008) 167:703–706 705discomfort is disproportionate to the extent of visible skin
manifestations because we obviously do not always see
what these patients feel. If cutaneous symptoms are
completely absent, an accurate diagnosis is difficult and
requires all diagnostic abilities of the attending physicians.
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